| Name | Title | Contact Details |
|---|
Geltor is the bio-design company that makes the world`s most advanced proteins for consumers, with a focus on unique functionality and sustainability.
Progenics Pharmaceuticals, Inc. is developing innovative medicines for oncology, with a pipeline that includes several product candidates in later-stage clinical development. Progenics` first-in-class PSMA-targeted technology platform for prostate cancer includes an antibody drug conjugate therapeutic which completed a two-cohort phase 2 clinical trial and a small molecule imaging agent that has also completed a phase 2 trial. Among other assets in its pipeline of targeted radiotherapy and molecular imaging compounds is Azedra™, an ultra-orphan radiotherapy candidate currently in a phase 2 study under an SPA. Progenics’ first commercial product, RELISTOR® (methylnaltrexone bromide) for opioid-induced constipation, is partnered with and marketed by Salix Pharmaceuticals, Ltd., a Valeant Pharmaceuticals International, Inc.
Libra Therapeutics is focused on developing novel disease-modifying therapeutics that can restore the cellular balance disrupted in neurodegenerative diseases.
BioStudio Visual Communications is a Portland, OR-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Capital Genomix (US Headquarters) is a Gaithersburg, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.